Aurora Cannabis ratings
Aurora Cannabis (ACB) has been on a downtrend since March this year, and the decline accelerated after it released its earnings on May 14. The company has lost almost 12% since then, while the Horizons Marijuana Life Sciences ETF (HMMJ) has lost about 6%. In contrast, Tilray (TLRY), which also reported its earnings on the same day, has risen by about 5%. Let’s look at the company’s ratings and price target change over the past month.
The current consensus rating from 14 analysts for Aurora Cannabis was a “buy,” which remained unchanged from the last month. Of the 14 analysts, four maintained a “strong buy” on the stock while six maintained a “buy” on the company in the current month. However, the number of analysts recommending a “hold” rose to three from two while one continued to have a “sell” rating on the stock. Aurora’s peer Tilray and Cronos Group (CRON) both had a “hold” recommendation each in the current month.
Month-over-month, Aurora Cannabis’s consensus price target was slightly lower at 14.3 Canadian dollars from 14.7 Canadian dollars a month ago. However, based on the closing of 9.7 Canadian dollars on June 21, the current price target would still entail an upside of about 48% if the current price were to converge to this price target. Read HEXO’s Target Price Gets an Upgrade in May.